Spark Therapeutics and SpliceBio have formed a collaboration to develop a gene therapy that can treat an inherited retinal disease. On Oct. 17, 2023, SpliceBio, a genetic medicines company headquartered in Spain, announced that it has signed an exclusive collaboration and licensing agreement with Spark Therapeutics under which SpliceBio will
The California Institute for Regenerative Medicine has partnered with Forge Biologics, which will manufacture AAVs to help accelerate gene therapy programs in California. Forge Biologics (Forge), a US-based contract development and manufacturing organization (CDMO), announced on Oct. 11, 2023 that it has joined the California Institute for Regenerative Medicine’s
Wheeler plans to use the facility to bolster its mission in helping fledgling biotech innovators and startups accelerate their development at an equitable price. On Oct. 5, 2023, Wheeler Bio, a contract development and manufacturing organization (CDMO) for next-gen protein therapeutics, announced the grand opening of their new drug substance
SCHOTT now offers ViewCell, a new component meant to add flexibility to biopharmaceutical process control. On Oct. 18, 2023, SCHOTT announced that it has launched a new component for biopharmaceutical process analysis, the ViewCell flow cell. The purpose of this new component is to optimize downstream processes in the biopharmaceutical
These results will provide insights from more than 250 global pharma executives, including discoveries such as pharma confidence dipping below the record scores of 2022, although it has remained extremely resilient despite wider macro uncertainly, according to the press release. Key highlights from the CPHI Pharma Survey were announced as
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.
Sterling is known as a global contract development and manufacturing organization, and their network spreads to a manufacturing site in Cramlington, United Kingdom, a recently GMP-licensed dedicated bioconjugation facility in Deeside, and a 111-acre site in Ringaskiddy, Ireland. Sterling Pharma Solutions acquired UK-based NewChem Technologies, a contract services provider focused
The recommended medicines include treatments for Duchenne muscular dystrophy, relapsed or refractory multiple myeloma, hyperargininemia, invasive candidiasis, menopause symptoms, and diagnostic medicines for characterizing lesions. The European Medicines Agency (EMA) announced on Oct. 13, 2023 that the agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended seven
Under an expanded agreement, Cellares will provide proof-of-concept manufacturing for a second CAR-T cell therapy from Bristol Myers Squibb. On Oct. 11, 2023, Cellares, an integrated development and manufacturing organization (IDMO) specializing in cell therapy manufacturing, announced it has expanded its agreement with Bristol Myers Squibb (BMS) to include a
Mirati’s focus on breakthrough cancer treatments will bolster Bristol Myers Squibb’s oncology portfolio. On Oct 8, 2023, Bristol Myers Squibb and Mirati Therapeutics announced that Bristol Myers Squibb has acquired Mirati for a total equity value of $4.8 billion. Mirati stockholders will receive one non-tradable Contingent Value